ISU Abxis Co. Ltd Market Cap ($64.05 Million)
Market Cap & Net Worth: ISU Abxis Co. Ltd (086890)
ISU Abxis Co. Ltd market cap. ISU Abxis Co. Ltd (KQ:086890) has a market capitalization of $64.05 Million (₩94.52 Billion) as of November 3, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #20765 globally and #1171 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ISU Abxis Co. Ltd's stock price ₩3550.00 by its total outstanding shares 26625300 (26.63 Million). Also see ISU Abxis Co. Ltd (086890) cash flow conversion for how efficiently the company converts equity into cash flow.
ISU Abxis Co. Ltd Market Cap History (2015–2026)
ISU Abxis Co. Ltd market cap history from 2015 to 2026. Data shows change from $137.64 Million to $64.05 Million (-7.31% CAGR). Check today's stock price for ISU Abxis Co. Ltd for real-time trading data and today's change.
Index Memberships
ISU Abxis Co. Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$211.91 Billion | 0.03% | #522 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$211.91 Billion | 0.03% | #522 of 1384 |
Weight: ISU Abxis Co. Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
ISU Abxis Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ISU Abxis Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of ISU Abxis Co. Ltd to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.00x
ISU Abxis Co. Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.01x
ISU Abxis Co. Ltd's market cap is 0.01 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $137.64 Million | $11.47 Billion | -$9.77 Billion | 0.01x | N/A |
| 2016 | $144.68 Million | $19.05 Billion | -$2.04 Billion | 0.01x | N/A |
| 2017 | $158.42 Million | $19.46 Billion | -$8.73 Billion | 0.01x | N/A |
| 2018 | $114.76 Million | $16.75 Billion | -$12.99 Billion | 0.01x | N/A |
| 2019 | $119.99 Million | $21.02 Billion | -$17.82 Billion | 0.01x | N/A |
| 2020 | $129.73 Million | $25.61 Billion | -$19.87 Billion | 0.01x | N/A |
| 2021 | $158.60 Million | $28.02 Billion | $829.93 Million | 0.01x | 0.19x |
| 2022 | $103.75 Million | $41.17 Billion | -$7.25 Billion | 0.00x | N/A |
| 2023 | $109.16 Million | $54.31 Billion | $3.61 Billion | 0.00x | 0.03x |
| 2024 | $80.29 Million | $60.26 Billion | $14.72 Billion | 0.00x | 0.01x |
Competitor Companies of 086890 by Market Capitalization
Companies near ISU Abxis Co. Ltd in the global market cap rankings as of November 3, 2026. Also see ISU Abxis Co. Ltd asset portfolio for a full breakdown of the balance sheet.
Key companies related to ISU Abxis Co. Ltd by market ranking:
- Sam Chun Dang Pharm. Co. Ltd (KQ:000250): Ranked #5084 globally with a market cap of $2.67 Billion USD ( ₩3.94 Trillion KRW).
- ST Pharm Co.Ltd (KQ:237690): Ranked #8953 globally with a market cap of $916.61 Million USD ( ₩1.35 Trillion KRW).
- NatureCell Co.Ltd (KQ:007390): Ranked #9611 globally with a market cap of $793.12 Million USD ( ₩1.17 Trillion KRW).
- Oscotec Inc (KQ:039200): Ranked #10419 globally with a market cap of $674.16 Million USD ( ₩994.80 Billion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #5084 | Sam Chun Dang Pharm. Co. Ltd | KQ:000250 | $2.67 Billion | ₩183900.00 |
| #8953 | ST Pharm Co.Ltd | KQ:237690 | $916.61 Million | ₩72500.00 |
| #9611 | NatureCell Co.Ltd | KQ:007390 | $793.12 Million | ₩22050.00 |
| #10419 | Oscotec Inc | KQ:039200 | $674.16 Million | ₩35400.00 |
Market Capitalization of ISU Abxis Co. Ltd (2015–2026)
Market capitalization of ISU Abxis Co. Ltd from 2015 to today. Between 2015 and today, ISU Abxis Co. Ltd's market cap moved from $137.64 Million to $ 64.05 Million, with a yearly change of -7.31%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩64.05 Million | -31.07% |
| 2025 | ₩92.92 Million | +15.73% |
| 2024 | ₩80.29 Million | -26.45% |
| 2023 | ₩109.16 Million | +5.22% |
| 2022 | ₩103.75 Million | -34.58% |
| 2021 | ₩158.60 Million | +22.25% |
| 2020 | ₩129.73 Million | +8.12% |
| 2019 | ₩119.99 Million | +4.56% |
| 2018 | ₩114.76 Million | -27.56% |
| 2017 | ₩158.42 Million | +9.50% |
| 2016 | ₩144.68 Million | +5.12% |
| 2015 | ₩137.64 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of ISU Abxis Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $64.05 Million USD |
| MoneyControl | $64.05 Million USD |
| MarketWatch | $64.05 Million USD |
| marketcap.company | $64.05 Million USD |
| Reuters | $64.05 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ISU Abxis Co. Ltd
ISU Abxis Co., Ltd., a biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide. The company offers Abcertin, an imiglucerase for injection that is used as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Type 1 Gaucher disease; Fabagal, an agalsidase beta for injection, which is used as a long term enzyme repla… Read more